drugset / Trial / NCT01939184

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184 ↗

Phase 2 Completed 796 enrolled Warner Chilcott
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.

Timeline

Start
2013-08
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject WC3055 Unknown 12.5 mg —
Subject WC3055 Unknown 25 mg —
Subject WC3055 Unknown 50 mg —
Subject WC3055 Unknown 75 mg —